Clinical Trial: A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1
Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Assessment of Interactions Between IV Methamphetamine and Reserpine
Brief Summary: In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
Detailed Summary: In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
Sponsor: National Institute on Drug Abuse (NIDA)
Current Primary Outcome:
- Craving
- Cardiovascular
- Subjective symptoms/Mood Effects
- CNS norepinephrine turnover
Original Primary Outcome:
- Craving
- Cardiovasular
- Subjective symptoms/Mood Effects
- CNS norepinephrine turnover
Current Secondary Outcome:
Original Secondary Outcome:
Information By: National Institute on Drug Abuse (NIDA)
Dates:
Date Received: December 20, 2005
Date Started: January 2004
Date Completion: November 2004
Last Updated: January 10, 2017
Last Verified: December 2005